Telomeres and telomerase in T cells of tumor immunity

Cellular Immunology

Volumn 289, Issue 1-2, 2014, Pages 63-69

  Qian, Yaqin ^a,b,c,d   Yang, Lili ^a,b,c,d   Cao, Shui ^a,b,c,d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b National Cancer Center   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^d Research Center of Lung Cancer   (China)

Author keywords

HTERT overexpression; Immunotherapy; T cells; Telomerase; Telomere

Indexed keywords

BETA CATENIN; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MAX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE ZAP 70; PROTEIN MAD1; PROTEIN P53; PROTEIN P73; RETINOBLASTOMA PROTEIN; SMAD PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR CTCF; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSFORMING GROWTH FACTOR BETA; WT1 PROTEIN;

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; CANCER IMMUNOTHERAPY; CELL REGENERATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME REGULATION; ESTROGEN RESPONSIVE ELEMENT; HEMATOPOIETIC CELL; HUMAN; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TUMOR IMMUNITY;

HTERT OVEREXPRESSION; IMMUNOTHERAPY; T CELLS; TELOMERASE; TELOMERE;

CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TELOMERASE; TELOMERE;

EID: 84898636273     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.03.009     Document Type: Review

References (81)

1. Moyzis R.K., Buckingham J.M., Cram L.S., Dani M., Deaven L.L., Jones M.D., Meyne J., Ratliff R.L., Wu J.R. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:6622-6626.
2. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-514.
3. Smogorzewska A., de Lange T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 2004, 73:177-208.
4. Campisi J. Cancer and ageing: rival demons?. Nat. Rev. Cancer 2003, 3:339-349.
5. D'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
6. Raynaud C.M., Sabatier L., Philipot O., Olaussen K.A., Soria J.C. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit. Rev. Oncol. Hematol. 2008, 66:99-117.
7. Chiu C.P., Harley C.B. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc. Soc. Exp. Biol. Med. 1997, 214:99-106.
8. Wellinger R.J., Sen D. The DNA structures at the ends of eukaryotic chromosomes. Eur. J. Cancer 1997, 33:735-749.
9. Williamson J.R., Raghuraman M.K., Cech T.R. Monovalent cation-induced structure of telomeric DNA: the G-quartet model. Cell 1989, 59:871-880.
10. Palm W., de Lange T. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 2008, 42:301-334.
11. Nandakumar J., Cech T.R. Finding the end: recruitment of telomerase to telomeres. Nat. Rev. Mol. Cell Biol. 2013, 14:69-82.
12. Hande M.P., Samper E., Lansdorp P., Blasco M.A. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol. 1999, 144:589-601.
13. Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., Harley C.B. Telomere end-replication problem and cell aging. J. Mol. Biol. 1992, 225:951-960.
14. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., Greider C.W., Harley C.B. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10114-10118.
15. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
16. Conomos D., Pickett H.A., Reddel R.R. Alternative lengthening of telomeres: remodeling the telomere architecture. Front. Oncol. 2013, 3:27.
17. Mason P.J., Bessler M. The genetics of dyskeratosis congenita. Cancer Genet. 2011, 204:635-645.
18. Djojosubroto M.W., Choi Y.S., Lee H.W., Rudolph K.L. Telomeres and telomerase in aging, regeneration and cancer. Mol. Cells 2003, 15:164-175.
19. Counter C.M., Gupta J., Harley C.B., Leber B., Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85:2315-2320.
20. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000, 60:610-617.
21. Albanell J., Lonardo F., Rusch V., Engelhardt M., Langenfeld J., Han W., Klimstra D., Venkatraman E., Moore M.A., Dmitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 1997, 89:1609-1615.
22. Uen Y.H., Lin S.R., Wu D.C., Su Y.C., Wu J.Y., Cheng T.L., Chi C.W., Wang J.Y. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann. Surg. 2007, 246:1040-1046.
23. Calado R.T., Young N.S. Telomere maintenance and human bone marrow failure. Blood 2008, 111:4446-4455.
24. Artandi S.E., DePinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
25. Günes C., Rudolph K.L. The role of telomeres in stem cells and cancer. Cell 2013, 152:390-393.
26. Kong C.M., Lee X.W., Wang X. Telomere shortening in human diseases. FEBS J. 2013, 280:3180-3193.
27. Effros R.B., Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?. Immunol. Today 1997, 18:450-454.
28. Yang L., Mailloux A., Rollison D.E., Painter J.S., Maciejewski J., Paquette R.L., Loughran T.P., McGraw K., Makishima H., Radhakrishnan R., Wei S., Ren X., Komrokji R., List A.F., Epling-Burnette P.K. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia 2013, 27:897-906.
29. Moro-Garcia M.A., Alonso-Arias R., Lopez-Larrea C. Molecular mechanisms involved in the aging of the T-cell immune response. Curr. Genomics 2012, 13:589-602.
30. Rufer N., Dragowska W., Thornbury G., Roosnek E., Lansdorp P.M. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 1998, 16:743-747.
31. Weng N.P., Levine B.L., June C.H., Hodes R.J. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11091-11094.
32. Monteiro J., Batliwalla F., Ostrer H., Gregersen P.K. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J. Immunol. 1996, 156:3587-3590.
33. Hodes R.J., Hathcock K.S., Weng N.P. Telomeres in T and B cells. Nat. Rev. Immunol. 2002, 2:699-706.
34. Wolf D., Rumpold H., Koppelstatter C., Gastl G.A., Steurer M., Mayer G., Gunsilius E., Tilg H., Wolf A.M. Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol. Immunother. 2006, 55:1198-1208.
35. Barsov E.V. Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. Immunotherapy 2011, 3:407-421.
36. Shen X., Zhou J., Hathcock K.S., Robbins P., Powell D.J., Rosenberg S.A., Hodes R.J. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 2007, 30:123-129.
37. Weng N.P., Hathcock K.S., Hodes R.J. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 1998, 9:151-157.
38. Weng N.P., Levine B.L., June C.H., Hodes R.J. Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 1996, 183:2471-2479.
39. Hathcock K.S., Weng N.P., Merica R., Jenkins M.K., Hodes R. Cutting edge: antigen-dependent regulation of telomerase activity in murine T cells. J. Immunol. 1998, 160:5702-5706.
40. Fujii H., Shao L., Colmegna I., Goronzy J.J., Weyand C.M. Telomerase insufficiency in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4360-4365.
41. Tamayo M., Mosquera A., Rego J.I., Fernandez-Sueiro J.L., Blanco F.J., Fernandez J.L. Differing patterns of peripheral blood leukocyte telomere length in rheumatologic diseases. Mutat. Res. 2010, 683:68-73.
42. Lin T.T., Letsolo B.T., Jones R.E., Rowson J., Pratt G., Hewamana S., Fegan C., Pepper C., Baird D.M. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010, 116:1899-1907.
43. Röth A., de Beer D., Nückel H., Sellmann L., Dührsen U., Dürig J., Baerlocher G.M. Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+chronic lymphocytic leukaemia. Br. J. Haematol. 2008, 143:383-386.
44. Cifuentes-Rojas C., Shippen D.E. Telomerase regulation. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2012, 730:20-27.
45. Qi D.L., Ohhira T., Fujisaki C., Inoue T., Ohta T., Osaki M., Ohshiro E., Seko T., Aoki S., Oshimura M., Kugoh H. Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol. Cell. Biol. 2011, 31:1624-1636.
46. Cukusic A., Skrobot Vidacek N., Sopta M., Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet. Genome Res. 2008, 122:263-272.
47. Wang C., Hou X., Mohapatra S., Ma Y., Cress W.D., Pledger W.J., Chen J. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J. Biol. Chem. 2005, 280:12339-12343.
48. Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., Ariga H., Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000, 28:669-677.
49. Daniel M., Peek G.W., Tollefsbol T.O. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012, 498:135-146.
50. Kikuno N., Shiina H., Urakami S., Kawamoto K., Hirata H., Tanaka Y., Majid S., Igawa M., Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 2008, 123:552-560.
51. Gladych M., Wojtyla A., Rubis B. Human telomerase expression regulation. Biochem. Cell Biol. 2011, 89:359-376.
52. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99:1528-1538.
53. Bougel S., Lhermitte B., Gallagher G., de Flaugergues J.C., Janzer R.C., Benhattar J. Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids. Clin. Cancer Res. 2013, 19:2216-2223.
54. Chebel A., Rouault J.P., Urbanowicz I., Baseggio L., Chien W.W., Salles G., Ffrench M. Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells. J. Biol. Chem. 2009, 284:35725-35734.
55. Terme J.M., Mocquet V., Kuhlmann A.S., Zane L., Mortreux F., Wattel E., Duc Dodon M., Jalinot P. Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. Leukemia 2009, 23:2081-2089.
56. Lamy E., Goetz V., Erlacher M., Herz C., Mersch-Sundermann V. HTERT: another brick in the wall of cancer cells. Mutat. Res. 2013, 752:119-128.
57. Wu S., Hultquist A., Hydbring P., Cetinkaya C., Oberg F., Larsson L.G. TGF-beta enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity. Exp. Cell Res. 2009, 315:3099-3111.
58. Bai D., Ueno L., Vogt P.K. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int. J. Cancer 2009, 125:2863-2870.
59. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66:407-425. (table of contents).
60. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
61. Alfonso-De Matte M.Y., Yang H., Evans M.S., Cheng J.Q., Kruk P.A. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res. 2002, 62:4575-4578.
62. Hoffmeyer K., Raggioli A., Rudloff S., Anton R., Hierholzer A., Del Valle I., Hein K., Vogt R., Kemler R. Wnt/-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012, 336:1549-1554.
63. Blasco M.A. The epigenetic regulation of mammalian telomeres. Nat. Rev. Genet. 2007, 8:299-309.
64. Greider C.W. Wnt regulates TERT-putting the horse before the cart. Science 2012, 336:1519-1520.
65. Listerman I., Sun J., Gazzaniga F.S., Lukas J.L., Blackburn E.H. The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis. Cancer Res. 2013, 73:2817-2828.
66. Chiang Y.J., Hemann M.T., Hathcock K.S., Tessarollo L., Feigenbaum L., Hahn W.C., Hodes R.J. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol. Cell. Biol. 2004, 24:7024-7031.
67. Cairney C.J., Keith W.N. Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 2008, 90:13-23.
68. Atkinson S.P., Hoare S.F., Glasspool R.M., Keith W.N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005, 65:7585-7590.
69. Shitara S., Kakeda M., Nagata K., Hiratsuka M., Sano A., Osawa K., Okazaki A., Katoh M., Kazuki Y., Oshimura M., Tomizuka K. Telomerase-mediated life-span extension of human primary fibroblasts by human artificial chromosome (HAC) vector. Biochem. Biophys. Res. Commun. 2008, 369:807-811.
70. Kang M.K., Park N.H. Extension of cell life span using exogenous telomerase. Methods Mol. Biol. 2007, 371:151-165.
71. Rufer N., Brummendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., Schulzer M., Lansdorp P.M. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 1999, 190:157-167.
72. Toptan T., Ensser A., Fickenscher H. Rhadinovirus vector-derived human telomerase reverse transcriptase expression in primary T cells. Gene Ther. 2010, 17:653-661.
73. Roth A. Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT. Blood 2005, 106:43-50.
74. Rufer N., Migliaccio M., Antonchuk J., Humphries R.K., Roosnek E., Lansdorp P.M. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001, 98:597-603.
75. Schreurs M.W., Hermsen M.A., Geltink R.I., Scholten K.B., Brink A.A., Kueter E.W., Tijssen M., Meijer C.J., Ylstra B., Meijer G.A., Hooijberg E. Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes. Blood 2005, 106:2663-2670.
76. Luiten R.M. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 2003, 101:4512-4519.
77. Menzel O., Migliaccio M., Goldstein D.R., Dahoun S., Delorenzi M., Rufer N. Mechanisms regulating the proliferative potential of human CD8+ T lymphocytes overexpressing telomerase. J. Immunol. 2006, 177:3657-3668.
78. Thadikkaran L., Menzel O., Tissot J.D., Rufer N. Proteomic and transcriptomic analysis of human CD8(+) T lymphocytes over-expressing telomerase. Proteomics Clin. Appl. 2007, 1:299-311.
79. Berry L.J., Moeller M., Darcy P.K. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 2009, 74:277-289.
80. Lee A.F., Sieling P.A., Lee D.J. Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology 2013, 2:e22889.
81. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr. Opin. Immunol. 2009, 21:200-208.